已收盤 08-07 16:00:00 美东时间
+0.100
+0.76%
enGene Holdings press release (ENGN): Q2 GAAP EPS of $0.43. As of April 30, 2026, cash, cash equivalents and marketable securities were $285.2 million providing significant operational flexibility. To...
06-15 22:12
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
05-08 23:34
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.
05-08 01:39
Name change reflects transition towards potential commercial organization in 2027Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026enGene Therapeutics Inc. (formerly, enGene Holdings Inc.)
04-07 20:11